Cost-utility analysis of daily versus intermittent inhaled corticosteroids in mild-persistent asthma

Pediatric Pulmonology

Volumn 50, Issue 8, 2015, Pages 735-746

  Rodriguez Martinez, Carlos E ^a,b   Nino, Gustavo ^c   Castro Rodriguez, Jose A ^d  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b HOSPITAL MILITAR CENTRAL   (Colombia)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

asthma; cost effectiveness; developing countries; inhaled corticosteroids; quality adjusted life years

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; PREDNISOLONE; SALBUTAMOL; GLUCOCORTICOID;

ARTICLE; ASTHMA; CONSULTATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIDDEN MARKOV MODEL; HUMAN; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; METERED DOSE INHALER; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMICS; INHALATIONAL DRUG ADMINISTRATION; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, INHALATION; ASTHMA; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HUMANS; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84937024332     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23073     Document Type: Article

References (34)

1. Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF,. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmaeconomics 2006; 24: 695-708.
2. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE,. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway responsiveness and clinical asthma in nonsteroid dependent asthmatics. Am Rev Respir Dis 1990; 142: 832-836.
3. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reiniainen K, Selroos O, et al., Comparison of a β2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388-392.
4. Busse WW, Pedersen S, Pauwels RA, Tan WC, Chen YZ, Lamm CJ, O'Byrne PM, START Investigators Group. The inhaled steroid treatment as regular therapy in early asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2008; 121: 1167-1674.
5. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B,. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332-336.
6. Rodriguez Martinez CE, Sossa MP, Rand CS,. Validation of a questionnaire for assessing adherence to metered-dose inhaler use in asthmatic children. Pediatr Asthma Allergy Immunol 2007; 20: 243-253.
7. Zeiger RS, Mauger D, Bacharier LB, Guilbert TW, Martinez FD, Lemanske RF Jr, Strunk RC, Covar R, Szefler SJ, Boehmer S, et al., Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med 2011; 365: 1990-2001.
8. Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF Jr, Mauger DT, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, et al., Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377: 650-657.
9. Rodriguez Martinez CE, Sossa MP, Castro-Rodriguez JA,. Factors associated to recurrent visits to the emergency department for asthma exacerbations in children: implications for a health education programme. Allergol Immunopathol 2008; 36: 72-78.
10. Ketchell RI, Jensen MW, Lumley P, Wright AM, Allenby MI,., O'connor BJ,. Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5'-monophosphate in mild asthma. J Allergy Clin Immunol 2002; 110: 603-606.
11. Ducharme FM,. Continuous versus intermittent inhaled corticosteroids for mild persistent asthma: not too much, not too little. Thorax 2012; 67: 102-105.
12. Aït-Khaled N, Auregan G, Bencharif N, Camara LM, Dagli E, Djankine K, Keita B, Ky C, Mahi S, Ngoran K, et al., Affordability of inhaled corticosteroids as a potential barrier to treatment of asthma in some developing countries. Int J Tuberc Lung Dis 2000; 4: 268-271.
13. Papi A, Nicolini G, Baraldi E, Boner AL, Cutrera R, Rossi GA, Fabbri LM, BEclomethasone and Salbutamol Treatment (BEST) for Children Study Group. Regular vs prn nebulized treatment in wheeze preschool children. Allergy 2009; 64: 1463-14771.
14. Turpeinen M, Nikander K, Pelkonen AS, Syvänen P, Sorva R, Raitio H, Malmberg P, Juntunen-Backman K, Haahtela T,. Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study). Arch Dis Child 2008; 93: 654-659.
15. Rubio-Terrés C, Echevarría A,. Modelos de Markov: Una herramienta útil para el análisis farmacoeconõmico. Pharmacoeconomics-Spanish Research Articles 2006; 3: 71-78.
16. Briggs A, Sculpher M,. An introduction to Markov modeling for economic evaluation. Pharmacoeconomics 1998; 13: 397-409.
17. Price MJ, Briggs AH,. Development of an economic model to assess the cost-effectiveness of asthma management strategies. Pharmaeconomics 2002; 20: 183-194.
18. Rodriguez-Martinez CE, Sossa-Briceño MP, Castro-Rodriguez JA,. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma. J Asthma 2013; 50: 410-418.
19. Potter PC,. Current guidelines for the management of asthma in young children. Allergy Asthma Immunol Res 2010; 2: 1-13.
20. Briggs A, Claxton K, Sculpher M,. Decision modeling for health economic evaluation. New York: Oxford University Press; 2006.
21. Chiou CF, Weaver MR, Bell MA, Lee TA, Krieger JW,. Development of the multiatribute pediatric asthma health outcome measure (PAHOM). Int J Qual Health Care 2005; 17: 23-30.
22. Sistema de Informaciõn de precios de medicamentos-SISMED. Listado de precios promedio y unidades en la cadena de comercializaciõn de medicamentos. Ministerio de la Protecciõn Social. República de Colombia. Available at: http://www.consultorsalud.com/biblioteca/documentos/2012/Precios%20reportados%20de%20medicamentos%20diciembre%202011.pdf. Accessed November 4, 2013.
23. Adams N, Lasserson TJ, Cates CJ, Jones PW,. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2007; Art. No. CD002310. DOI: 10.1002/14651858.CD002310.pub4.
24. Manning P, Gibson PG, Lasserson TJ,. Ciclesonide versus other inhaled steroids for chronic asthma in children and adults. Cochrane Database Syst Rev 2008; Art. No. CD007031. DOI: 10.1002/14651858.CD007031.
25. Guía de Práctica Clínica (GPC) para el diagnõstico, atenciõn integral y seguimiento de niños y niñas con diagnõstico de asma. http://gpc.minsalud.gov.co/guias/Pages/Guía-de-asma-en-niños.aspx. Accessed November 16, 2013.
26. British Guideline on the Management of Asthma. A national clinical guideline. British Thoracic Society. Scottish Intercollegiate Guidelines Network. Available at: http://www.sign.ac.uk/pdf/sign101.pdf. Accessed November 4, 2013.
27. Linstone H, Turoff M,. The Delphi method. Techniques and applications. Los Angeles, CA: University of Southern California; 2002.
28. Banco de la República, Colombia. Series estadísticas. Tasas de cambio. Santa Fe de Bogotá: Banco de la República; 2011. Available in: http://www.banrep.gov.co/series-estadisticas/see-ts-cam.htm. Accessed November 4, 2013.
29. OBrien BJ, Drummond MF, Labelle RJ, Willan A,. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994; 32: 150-163.
30. Briggs AH, Goeree R, Blackhouse G, OBrien B,. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002; 22: 290-308.
31. Rodrigo GJ, Castro-Rodríguez JA,. Daily vs. intermittent inhaled corticosteroids for recurrent wheezing and mild persistent asthma: a systematic review with meta-analysis. Respir Med. 2013; 107: 1133-1140.
32. Chauhan BF, Chartrand C, Ducharme FM,. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev 2013; Art. No.: CD009611. DOI: 10.1002/14651858.CD009611.pub3
33. Garbutt J, Highstein G, Nelson KA, Rivera-Spoljaric K, Strunk R,. Detection and home management of worsening asthma symptoms. Ann Allergy Asthma Immunol 2009; 103: 469-473.
34. FitzGerald JM, Boulet LP, Follows RM,. The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther 2005; 27: 393-406.